Ankylosing Spondylitis Market Epidemiology Report, Size, Share, Trends and Forecast 2025-2035

According to the IMARC Group, the ankylosing spondylitis market size reached a value of USD 5.1 Billion in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 10.2 Billion by 2035, exhibiting a growth rate (CAGR) of 6.53% during 2025-2035. This can be attributed to the rising popularity of numerous innovative approaches to treatment, including combination therapy in patients who have failed other medications.

Ankylosing spondylitis (AS) represents a chronic inflammatory disease that largely affects the joints of the spine, leading to stiffness and pain. The ankylosing spondylitis market is primarily driven by the increasing prevalence of autoimmune diseases, advancements in biologic and targeted therapies, and growing awareness about early diagnosis and disease management. Besides this, the widespread adoption of tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) inhibitors has significantly improved patient outcomes, fueling the ankylosing spondylitis market growth.

The rising preference for biosimilars, which offer cost-effective alternatives to branded biologics, is further expanding treatment accessibility, particularly in emerging markets. Moreover, continuous research and development (R&D) efforts are leading to the introduction of novel small-molecule drugs, such as Janus kinase (JAK) inhibitors, which provide new treatment options for patients who do not respond to traditional biologics, thereby catalyzing the ankylosing spondylitis market expansion. In parallel, government initiatives and healthcare reimbursement policies are improving patient access to advanced therapeutics. Additionally, the integration of artificial intelligence (AI) and machine learning (ML) in drug discovery and precision medicine is accelerating the development of personalized treatment approaches, thus stimulating the ankylosing spondylitis market growth. Furthermore, the trend towards precision medicine, which tailors therapies based on genetic and molecular profiling, is anticipated to propel the expansion of the ankylosing spondylitis market in the coming years.

Request for a sample of this report: https://www.imarcgroup.com/ankylosing-spondylitis-market/requestsample

Countries Covered:

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country:

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the hypoparathyroidism market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the hypoparathyroidism market
• Reimbursement scenario in the market
• In-market and pipeline drugs

This report also provides a detailed analysis of the current ankylosing spondylitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs:

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs:

• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance

Competitive Landscape with key players:

The competitive landscape of the ankylosing spondylitis market has been studied in the report with the detailed profiles of the key players operating in the market.

1. AbbVie
2. Pfizer
3. Eli Lilly and Company
4. Janssen Biotech
5. Novartis Pharmaceutical
6. UCB
7. Akeso Biopharma

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145